Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019. J Am Coll Cardiol. 2020;76:2982–3021.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organization. Cardiovascular diseases. World Health Organization. 2021. Available at : https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds). Accessed 30 Jan 2024.

Roth GA, Nguyen G, Forouzanfar MH, Mokdad AH, Naghavi M, Murray CJL. Estimates of global and regional premature cardiovascular mortality in 2025. Circulation. 2015;132:1270–1.

Article  PubMed  Google Scholar 

Civeira F, Arca M, Cenarro A, Hegele RA. A mechanism-based operational definition and classification of hypercholesterolemia. J Clin Lipidol. 2022;16:813–21.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72.

Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:1141–56.

Hansen MK, Mortensen MB, Warnakula Olesen KK, Thrane PG, Maeng M. Non-HDL cholesterol and residual risk of cardiovascular events in patients with ischemic heart disease and well-controlled LDL cholesterol: a cohort study. Lancet Reg Health Eur. 2024;36:100774.

Scicali R, Bosco G, Scamporrino A, Di Mauro S, Filippello A, Di Giacomo Barbagallo F, et al. Evaluation of high‐density lipoprotein‐bound long non‐coding RNAs in subjects with familial hypercholesterolaemia. Eur J Clin Invest. 2024;54:e14083.

Santos RD, Gidding SS, Hegele RA, Cuchel MA, Barter PJ, Watts GF, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. Lancet Diabetes Endocrinol. 2016;4:850–61.

Article  PubMed  Google Scholar 

Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease. J Am Coll Cardiol. 2012;60:2631–9.

Article  CAS  PubMed  Google Scholar 

Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions. JAMA. 2016;316:1289.

Article  CAS  PubMed  Google Scholar 

Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–81.

Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97.

Article  CAS  PubMed  Google Scholar 

Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22.

Article  CAS  PubMed  Google Scholar 

Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107.

Article  CAS  PubMed  Google Scholar 

Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388:1353–64.

Article  PubMed  Google Scholar 

Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al. A Comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med. 2020;382:9–19.

Article  CAS  PubMed  Google Scholar 

Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Variation among cardiovascular risk calculators in relative risk increases with identical risk factor increases Cardiovascular Disorders. BMC Res Notes. 2015;8:417.

Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. ACC/AHA Guideline on the Assessment of Cardiovascular Risk. Circulation. 2013;2014:129.

Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

Article  PubMed  Google Scholar 

Zhang Y, Miao H, Chia YC, Buranakitjaroen P, Siddique S, Shin J, et al. Cardiovascular risk assessment tools in Asia. J Clin Hypertens. 2022;24:369–77.

Article  Google Scholar 

Allan GM, Nouri F, Korownyk C, Kolber MR, Vandermeer B, McCormack J. Agreement among cardiovascular disease risk calculators. Circulation. 2013;127:1948–56.

Article  PubMed  Google Scholar 

Hageman S, Pennells L, Ojeda F, Kaptoge S, Kuulasmaa K, de Vries T, et al. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439–54.

Article  CAS  Google Scholar 

Yang X, Li J, Hu D, Chen J, Li Y, Huang J, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in chinese population. Circulation. 2016;134:1430–40.

Article  PubMed  Google Scholar 

Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the american heart association. Circulation. 2023;148:1982–2004.

Article  PubMed  Google Scholar 

Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. 2022;43:1715–27.

Packard CJ, Weintraub WS, Laufs U. New metrics needed to visualize the long-term impact of early LDL-C lowering on the cardiovascular disease trajectory. Vascul Pharmacol. 2015;71:37–9.

Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, et al. Familial hypercholesterolæmia in children and adolescents: Gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36:2425–37.

Sniderman AD, Islam S, McQueen M, Pencina M, Furberg CD, Thanassoulis G, et al. Age and cardiovascular risk attributable to apolipoprotein b, low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol. J Am Heart Assoc. 2016;5:e003665.

Antza C, Gallo A, Boutari C, Ershova A, Gurses KM, Lewek J, et al. Prevention of cardiovascular disease in young adults: Focus on gender differences. A collaborative review from the EAS Young Fellows. Atherosclerosis Elsevier Ireland Ltd. 2023.

Gooding HC, Gidding SS, Moran AE, Redmond N, Allen NB, Bacha F, et al. Challenges and opportunities for the prevention and treatment of cardiovascular disease among young adults: Report from a national heart, lung, and blood institute working group. J Am Heart Assoc. 2020;9.

Koskinen JS, Kytö V, Juonala M, Viikari JSA, Nevalainen J, Kähönen M, et al. Childhood dyslipidemia and carotid atherosclerotic plaque in adulthood: The cardiovascular risk in young finns study. J Am Heart Assoc. 2023;12.

Borén J, John Chapman M, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel.  Eur Heart J. 2020;41:2313–30.

Domanski MJ, Tian X, Wu CO, Reis JP, Dey AK, Gu Y, et al. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk. J Am Coll Cardiol. 2020;76:1507–16.

Article  CAS  PubMed  Google Scholar 

Yusuf PS, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004;364:937–52.

Article  PubMed  Google Scholar 

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111–88.

Article  PubMed  Google Scholar 

Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623–30.

Article  CAS  PubMed  Google Scholar 

Deedwania P, Stone PH, Bairey Merz CN, Cosin-Aguilar J, Koylan N, Luo D, et al. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease. Circulation. 2007;115:700–7.

Article  CAS  PubMed  Google Scholar 

Armitage J, Baigent C, Barnes E, Betteridge DJ, Blackwell L, Blazing M, et al. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. The Lancet. 2019;393:407–15.

Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–90.

Article  CAS  PubMed  Google Scholar 

Giral P, Neumann A, Weill A, Coste J. Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France. Eur Heart J. 2019;40:3516–25.

Article  PubMed  PubMed Central  Google Scholar 

Andersson NW, Corn G, Dohlmann TL, Melbye M, Wohlfahrt J, Lund M. LDL-C Reduction with lipid-lowering therapy for primary prevention of major vascular events among older individuals. J Am Coll Cardiol. 2023;82:1381–91.

Mortensen MB, Nordestgaard BG. Elevated LDL cholesterol and increased risk of myocardial infarction and atherosclerotic cardiovascular disease in individuals aged 70–100 years: a contemporary primary prevention cohort. Lancet. 2020;396:1644–52.

Article  CAS  PubMed  Google Scholar 

Savarese G, Gotto AM, Paolillo S, D’Amore C, Losco T, Musella F, et al. Benefits of statins in elderly subjects without established cardiovascular disease. J Am Coll Cardiol. 2013;62:2090–9.

Article  CAS  PubMed  Google Scholar 

Bosco G, Di Giacomo BF, Spampinato S, Lanzafame L, Di Pino A, Piro S, et al. Management of statin intolerant patients in the era of novel lipid lowering therapies: a critical approach in clinical practice. J Clin Med. 2023;12:2444.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hafiane A, Daskalopoulou SS. Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis. Pharmacol Res: Academic Press; 2022.

Book  Google Scholar 

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet 9 janv. 2010;375(9709):132–40. 

Jin Y, Fu J. Novel Insights Into the NLRP3 Inflammasome in Atherosclerosis. J Am Heart Assoc. 2019;8:e012219.